{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.9","upperLimit":"11.7","value":"9.4"},{"groupId":"OG001","lowerLimit":"1.7","upperLimit":"3.5","value":"2.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"64"}],"units":"Participants"}],"description":"EFS was assessed by the IRF and is defined as the time from randomization until any cause of treatment failure: disease progression, discontinuation of treatment for any reason, or death due to any cause, whichever occurs first. Disease progression was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).","dispersionType":"95% Confidence Interval","groups":[{"description":"Brentuximab vedotin 1.8 mg/kg, intravenous over approximately 30 minutes, once on Day 1 of each 21-day cycle and may continue as monotherapy for up to a total of 16 cycles (48 weeks).","id":"OG000","title":"Brentuximab Vedotin"},{"description":"Methotrexate 5 to 50 mg, tablets, orally, once weekly (dose adjustment is guided by patient response and toxicity) or Bexarotene 300 mg/m\\^2, tablets, orally, once daily with meals for up to 48 weeks.","id":"OG001","title":"Methotrexate or Bexarotene"}],"paramType":"MEDIAN","populationDescription":"The ITT population included all participants who were identified as CD30+ by the Ventana anti-CD30 (Ber-H2) assay and were randomized to treatment.","reportingStatus":"POSTED","timeFrame":"From randomization until disease progression, death or data cutoff (Median follow-up 36.8 months)","title":"Event-Free Survival (EFS)","type":"SECONDARY","unitOfMeasure":"months"}